Division of Cardiology, Knight Cardiovascular Institute, OHSU, Portland, OR, United States.
Curr Cardiol Rep. 2022 Sep;24(9):1209-1226. doi: 10.1007/s11886-022-01739-9. Epub 2022 Jun 29.
In this review, we have focused on the currently available transcatheter tricuspid valve therapies, device selection, as well as role and management of tricuspid regurgitation (TR) in the setting of other transcatheter valvular procedures.
In this review, we have enlisted the recently finished as well as ongoing trials in the percutaneous tricuspid valve therapies. TR is highly prevalent yet remains underrecognized and is often untreated. TR has traditionally been managed conservatively with medical therapies including diuretics for volume management, whereas surgical therapies are reserved for those undergoing left-sided valvular surgery. Although the transcatheter devices for tricuspid repair and replacement are in clinical trials, the experience to date for their effectiveness and safety has been reassuring.
在这篇综述中，我们重点关注了目前可用的经导管三尖瓣治疗方法、器械选择，以及在其他经导管瓣膜手术中三尖瓣反流（TR）的作用和管理。
在这篇综述中，我们列出了最近完成和正在进行的经皮三尖瓣治疗试验。TR 的患病率很高，但仍然未被认识，且往往未得到治疗。TR 传统上采用保守治疗，包括利尿剂进行容量管理，而手术治疗则保留给那些接受左侧瓣膜手术的患者。虽然三尖瓣修复和置换的经导管器械正在临床试验中，但迄今为止，其有效性和安全性的经验令人放心。
